You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HR HER2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

Not yet recruiting
  • HR+/HER2-breast Cancer
  • Standard endocrine therapy plus Apatinib
  • (no location specified)
Jun 2, 2023

HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

Recruiting
  • HR Positive HER2 Negative Advanced Breast Cancer
  • Tianjin, China
    天津市肿瘤医院
May 26, 2023

HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)

Not yet recruiting
  • HR+/HER2- Breast Cancer
  • (no location specified)
Nov 21, 2022

Risarg® Combined With Endocrine Therapy or Chemotherapy in

Not yet recruiting
  • HR+HER2- Advanced Breast Cancer
  • Ribociclib
  • Combination chemotherapy
  • (no location specified)
Nov 20, 2023

Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)

Recruiting
  • Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023

Ribociclib in Combination With Hormonal Therapy in HR+/HER2-

Not yet recruiting
  • Breast Cancer
  • ribociclib
  • (no location specified)
Oct 10, 2023

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023

Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast

Completed
  • HR+/HER2- Advanced or Metastatic Breast Cancer
    • Dublin, Ireland
      Novartis Pharmaceuticals
    May 2, 2023

    Breast Cancer Trial in Tianjin (Pyrrolidine?trastuzumab?AI)

    Recruiting
    • Breast Cancer
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Jun 1, 2023

    Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)

    Not yet recruiting
    • Hormone Receptor-positive Advanced Breast Cancer
    • (no location specified)
    Apr 12, 2023

    Breast Cancer Trial in Shantou (dose-dense nab-paclitaxel followed by EC)

    Recruiting
    • Breast Cancer
    • dose-dense nab-paclitaxel followed by EC
    • Shantou, Guangdong, China
      Shantou Central Hospital
    Feb 4, 2023

    Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

    Recruiting
    • Breast Cancer
    • pyrotinib combined with trastuzumab, dalpiciclib and letrozole
    • Yantai, Shandong, China
      Yantai Yuhuangding Hospital
    Mar 23, 2023

    Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

    Not yet recruiting
    • Advanced HR+ HER2 Negative Breast Carcinoma
    • (CDK)4/6 inhibitor
    • (no location specified)
    Sep 27, 2022

    Breast Cancer Trial (Fluzoparib, Anastrozole, Letrozole)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jun 5, 2023

    Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

    Not yet recruiting
    • Hormone Receptor-positive Advanced Breast Cancer
    • chidamide combined with fulvestrant
    • (no location specified)
    Mar 28, 2023

    Metastatic Breast Cancer, Unresectable Breast Cancer Trial in Saint Louis (DiviTum® TKa assay, CDK4/6 + Endocrine therapy)

    Not yet recruiting
    • Metastatic Breast Cancer
    • Unresectable Breast Cancer
    • DiviTum® TKa assay
    • CDK4/6 + Endocrine therapy
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jul 27, 2023

    Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

    Recruiting
    • Breast Cancer Metastatic Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Feb 26, 2023

    Breast Cancer Trial in Ann Arbor (Ribociclib, Postoperative Radiation Therapy)

    Not yet recruiting
    • Breast Cancer
    • Ann Arbor, Michigan
      University of Michigan
    Aug 10, 2023

    HR+/HER2- Advanced Breast Cancer Trial in Beijing (Dalpiciclib, Chidamide)

    Not yet recruiting
    • HR+/HER2- Advanced Breast Cancer
    • Beijing, Beijing, China
      The Fifth Medical Center of PLA General Hospital
    Oct 17, 2022

    HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

    Recruiting
    • HR+/HER2- Advanced Breast Cancer
    • Targeted Therapy
    • Beijing, Beijing, China
      National Cancer Center/National Clinical Research Center for Can
    Aug 1, 2023

    Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

    Recruiting
    • Breast Cancer Metastatic Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Feb 26, 2023

    Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and

    Not yet recruiting
    • Breast Cancer
    • Advanced Breast Cancer
    • Everolimus 10 mg
    • +2 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Jul 14, 2023

    CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • Different treatment regimens following progression on CDK4/6 inhibitors.
    • (no location specified)
    Sep 5, 2023

    Breast Cancer Trial in Milwaukee (Intermittent Fasting)

    Not yet recruiting
    • Breast Cancer
    • Intermittent Fasting
    • Milwaukee, Wisconsin
      Froedtert Hospital & the Medical College of Wisconsin
    Oct 24, 2023

    Among HR+/HER2- Advanced or Metastatic Breast Cancer in France

    Recruiting
    • Breast Cancer
    • ribociclib + ET
    • La Roche sur Yon Cedex, France
      Novartis Investigative Site
    Jan 16, 2023